ALXO Key Statistics, Chart & Performance
The current stock price of ALXO is 1.47 USD. In the past month the price increased by 1.38%. In the past year, price decreased by -2.97%.
ALXO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ALXO. When comparing the yearly performance of all stocks, ALXO is a bad performer in the overall market: 77.86% of all stocks are doing better.
ALXO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALXO. Both the profitability and financial health of ALXO have multiple concerns.
ALXO Financial Highlights
Over the last trailing twelve months ALXO reported a non-GAAP Earnings per Share(EPS) of -1.97. The EPS increased by 33.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -130.57% | ||
| ROE | -241.09% | ||
| Debt/Equity | 0.15 |
ALXO Forecast & Estimates
11 analysts have analysed ALXO and the average price target is 3.06 USD. This implies a price increase of 108.16% is expected in the next year compared to the current price of 1.47.
ALXO Ownership
About ALXO
Company Profile
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 44 full-time employees. The company went IPO on 2020-07-17. The firm's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
Company Info
ALX ONCOLOGY HOLDINGS INC
323 Allerton Avenue
South San Francisco CALIFORNIA 94010 US
CEO: Jaume Pons
Employees: 44
Phone: 16504667125
ALX ONCOLOGY HOLDINGS INC / ALXO FAQ
What does ALXO do?
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 44 full-time employees. The company went IPO on 2020-07-17. The firm's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
What is the current price of ALXO stock?
The current stock price of ALXO is 1.47 USD. The price increased by 11.36% in the last trading session.
Does ALX ONCOLOGY HOLDINGS INC pay dividends?
ALXO does not pay a dividend.
What is the ChartMill rating of ALX ONCOLOGY HOLDINGS INC stock?
ALXO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is ALX ONCOLOGY HOLDINGS INC (ALXO) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALXO.
Can you provide the market cap for ALX ONCOLOGY HOLDINGS INC?
ALX ONCOLOGY HOLDINGS INC (ALXO) has a market capitalization of 79.70M USD. This makes ALXO a Micro Cap stock.